SCYNEXIS, Inc. to Present at 35th Canaccord Genuity Annual Growth Conference

20:00 EDT 9 Aug 2015 | Globe Newswire

RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer, will present at the 35th Canaccord Genuity Annual Growth Conference at the InterContinental Boston Hotel in Boston on Wednesday, August 12, 2015, at 2:25 p.m. ET.

A live webcast will be available on the investors section of the Company's website: A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit

CONTACT: Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         Investor Relations
         Jillian Connell
         The Trout Group LLC
         Tel: 646.378.2956



More From BioPortfolio on "SCYNEXIS, Inc. to Present at 35th Canaccord Genuity Annual Growth Conference"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...